In Brief: Warner-Lambert's atorvastatin
Executive Summary
Warner-Lambert's atorvastatin: HMG-CoA reductase inhibitor for cholesterol lowering will be co-promoted by Pfizer under final deal made public July 2. The preliminary arrangement was announced April 11 ("The Pink Sheet" April 15, p. 14). Warner-Lambert filed the NDA for atorvastatin during the week of June 24. The agreement includes milestone payments, shared promotional expenses and the cost of long-term R&D studies. Pfizer will receive a portion of profits based on the achievement of sales targets...